Sort   by:  
 Page size 
MetabolomicsExploring Lipidomic Profiles and Their Correlation with Hormone Receptor and HER2 Status in Breast Cancer
Dysregulated lipid metabolism promotes the progression of various cancers, including breast cancer. This study aimed to explore the lipidomic profiles of breast cancer patients, providing insights into the correlation between lipid compositions and tumor subtypes characterized by hormone receptor (H...
2024-08-16 | MTBLS10858 | MetaboLights
TranscriptomicsTranscriptional analysis of signal transduction-related genes in experimental models of HER-2/neu-derived epithelial and mesenchymal tumors
Transcriptional expression of a restricted set of cancer signal transduction-related gesen were comparatively quantified in HER2/neu transgenic mammary tumors, mesenchymal and epithelial tumor cell lineages, both estabilished from HER-2/neu transgenic tumors, and syngeneic mesenchymal stem cells. In...
ORGANISM(S): Mus musculus 
2010-07-03 | E-GEOD-22663 | biostudies-arrayexpress
ProteomicsProteomic analysis of HCC-1954 and MCF-7 cell lines highlights crosstalk between αvβ1 integrin, E-cadherin and HER-2
Overexpression of human epidermal growth factor receptor 2 (HER-2) occurs in 20% of all breast cancer subtypes, those that present the worst prognostic outcome through a very invasive and aggressive tumour. HCC-1954 (HER-2+) is a highly invasive, metastatic cell line whereas MCF-7 is mildly aggressi...
ORGANISM(S): Homo sapiens (Human) 
2022-10-14 | PXD023876 | Pride
Hcc-1954 Membrane proteins Her-2 Breast cancer Mcf-7 Proteome 
TranscriptomicsThe N-glycosylated isoform of M-NM-2-integrin as a potential biomarker and target in HER-2+ BC refractory to HER-2 targeted therapies.
Acquired resistance to trastuzumab, a rationally designed HER-2 targeting antibody, remains a major hurdle in management of HER-2 positive breast cancer (HER-2+ BC) patients. Potential resistance mechanisms are numerous, derived primarily from studies where HER-2 positive cell lines are chronically...
ORGANISM(S): Homo sapiens 
2015-01-01 | E-GEOD-40152 | biostudies-arrayexpress
ClinicalA Study of Pyrotinib Combined With Capecitabine for Metastatic HER-2 Positive Colorectal Cancer
To evaluate the efficacy and safety of pyrotinib combined with capecitabine in patients with metastatic her-2 positive colorectal cancer after standard treatment.
2326840 | ecrin-mdr-crc
TranscriptomicsTranscription profiling of human breast cancer cells NF639 cells original population vs EGCG-resistant population
Overexpression of the epidermal growth factor receptor family member Her-2/neu in breast cancer leads to autophosphorylation of the receptor, and induction of multiple downstream signaling pathways including Akt kinase to NF-B cascade that is associated with poor prognosis. Previously, we demonst...
ORGANISM(S): Mus musculus 
2008-06-13 | E-GEOD-4140 | biostudies-arrayexpress
TranscriptomicsThe N-glycosylated isoform of β-integrin as a potential biomarker and target in HER-2+ BC refractory to HER-2 targeted therapies.
Acquired resistance to trastuzumab, a rationally designed HER-2 targeting antibody, remains a major hurdle in management of HER-2 positive breast cancer (HER-2+ BC) patients. Potential resistance mechanisms are numerous, derived primarily from studies where HER-2 positive cell lines are chronically ...
ORGANISM(S): Homo sapiens 
2015-01-01 | GSE40152 | GEO
TranscriptomicsGenome-wide analysis of time-dependent gene expression in MCF-10HER-2 cells treated with the HER-2-specific inhibitor CP724,714 for 45 hours
Results of blocking the kinase function of the activated HER-2 oncogene in MCF-10HER-2 cells by treatment with CP724,714 and measuring gene expression as a function of time provides information as to what genes are regulated by HER-2 in these breast epithelial cells that express transformed phenotyp...
ORGANISM(S): Homo sapiens 
2011-03-18 | E-GEOD-23137 | biostudies-arrayexpress
TranscriptomicsGenome-wide analysis of time-dependent gene expression in MCF-10HER-2/E7 cells treated with the HER-2-specific inhibitor CP724,714 for 45 hours
Results of blocking the activated HER-2 oncogene kinase activity in MCF-10HER-2/E7 cells by treatment with CP724,714 and measuring gene expression as a function of time provides information as to what genes are regulated by HER-2 in these transformed breast epithelial cells. MCF-10HER-2/E7 cells wer...
ORGANISM(S): Homo sapiens 
2010-08-24 | E-GEOD-23139 | biostudies-arrayexpress
ClinicalSingle center, single arm, prospective and open clinical study of pyrroltinib maleate tablets and trastuzumab combined with FOLFOX6 regimen in the preoperative treatment of HER-2 positive colorectal cancer
Interventions: HER-2 positive colorectal cancer:pyrroltinib maleate tablets and trastuzumab combined with FOLFOX6 regimen Primary outcome(s): pCR Study Design: Single arm
2698207 | ecrin-mdr-crc
Sort   by:  
 Page size